Table 4.
Proportion of patients with improvement in composite measure of improvement in A1C, LDL, or SBP among patients with that clinical condition uncontrolled at baseline
| CTL (n = 1,158 patients; 1,432 clinical domains) | INT (n = 1,220 patients; 1,501 clinical domains) | INT subgroups |
P value |
|||
|---|---|---|---|---|---|---|
| SC (n = 563 patients; 690 clinical domains) | No SC (n = 657 patients; 811 clinical domains) | INT vs. CTL | SC vs. no SC + CTL | |||
| Patient-specific analysis | ||||||
| Baseline and follow-up measurement | 1,158 | 1,220 | 563 | 657 | ||
| Yes | 1,012 (87.4) | 1,090 (89.3) | 510 (90.6) | 580 (88.3) | ||
| Improvement | 1,012 | 1,090 | 510 | 580 | ||
| Yes | 768 (75.9) | 832 (76.3) | 391 (76.7) | 441 (76.0) | 0.813 | 0.739 |
| Condition-specific analysis | ||||||
| Baseline and follow-up measurement | 1,432 | 1,501 | 690 | 811 | ||
| Yes | 1,082 (75.6) | 1,157 (77.1) | 543 (78.7) | 614 (75.7) | ||
| Improvement | 1,082 | 1,157 | 543 | 614 | ||
| Yes | 816 (75.4) | 876 (75.7) | 414 (76.2) | 462 (75.2) | 0.865 | 0.676 |
| Improvement by interventionist | ||||||
| Diabetes educator | 102/132 (77.3) | 116/148 (78.4) | 82/108 (75.9) | 34/40 (85.0) | 0.536 | 0.248 |
| Nurse health manager | 47/70 (67.1) | 49/68 (72.1) | 12/18 (66.7) | 37/50 (74.0) | ||
| Pharmacist | 667/880 (75.8) | 711/941 (75.6) | 320/417 (76.7) | 391/524 (74.6) | ||
| Improvement by sex | ||||||
| Female | 428/564 (75.9) | 441/596 (74.0) | 220/292 (75.3) | 221/304 (72.7) | 0.227 | 0.962 |
| Male | 388/518 (74.9) | 435/561 (77.5) | 194/251 (77.3) | 241/310 (77.7) | ||
| Improvement by race | ||||||
| Asian | 126/168 (75.0) | 112/161 (69.6) | 49/66 (74.2) | 63/95 (66.3) | 0.597 | 0.413 |
| Black | 98/136 (72.1) | 114/151 (75.5) | 50/71 (70.4) | 64/80 (80.0) | ||
| Other/unknown | 54/65 (83.1) | 69/79 (87.3) | 25/27 (92.6) | 44/52 (84.6) | ||
| White | 538/713 (75.5) | 581/766 (75.8) | 290/379 (76.5) | 291/387 (75.2) | ||
| Improvement by Hispanic ethnicity | ||||||
| No | 221/307 (72.0) | 264/341 (77.4) | 119/155 (76.8) | 145/186 (78.0) | 0.124 | 0.184 |
| Unknown | 500/653 (76.6) | 508/677 (75.0) | 248/323 (76.8) | 260/354 (73.4) | ||
| Yes | 95/122 (77.9) | 104/139 (74.8) | 47/65 (72.3) | 57/74 (77.0) | ||
| Improvement by age group | ||||||
| 18–39 | 38/53 (71.7) | 34/43 (79.1) | 16/20 (80.0) | 18/23 (78.3) | 0.501 | 0.202 |
| 40–64 | 420/560 (75.0) | 462/621 (74.4) | 209/269 (77.7) | 253/352 (71.9) | ||
| ≥65 | 358/469 (76.3) | 380/493 (77.1) | 189/254 (74.4) | 191/239 (79.9) | ||
Data are n (%) or n/T (%), unless otherwise indicated. CNT, control; INT, intervention; SC, successful contact; T, total number of uncontrolled conditions belonging to the indicted subgroup for which baseline and follow-up measurements are available.